Instrument Inactif

Autres langues Acura Pharmaceuticals, Inc. Nasdaq

Actions

US00509L8028

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Acura Pharmaceuticals, Inc. announced that it has received $0.2 million in funding	14/06
Acura Pharmaceuticals, Inc. and Acura Pharmaceutical Technologies, Inc Announce Executive Changes	04/06
Acura Pharmaceuticals, Inc. and Acura Pharmaceutical Technologies, Inc Announces CFO Changes	04/06
Acura Pharmaceuticals, Inc. announced that it has received $0.075 million in funding	03/06
Acura Pharmaceuticals, Inc. announced that it has received $0.2 million in funding	10/05
Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K	26/03
Acura Pharmaceuticals, Inc. Announces Amendment to the Agreement with Abuse Deterrent Pharma, LLC	26/03
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding from Abuse Deterrent Pharma, LLC	14/03
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC	14/02
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding	14/02
Acura Pharmaceuticals : AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE - Form 8-K	21/12
Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharmaceuticals, LLC Enter into Amendment #1 to the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note	21/12
Acura Pharmaceuticals : New Financial Obligation - Form 8-K	06/12
Acura Pharmaceuticals, Inc. Announces Retirement and Resignation of Mr. Bruce F. Wesson as Member of Board of Directors	25/09/23
Acura Pharmaceuticals, Inc. Provides Update Related to LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets	31/08/23
Acura Pharmaceuticals, Inc. Announces Preliminary Topline Results from Study AP-LTX-311 Successfully Demonstrated That A Nine-Tablet Dose of Ltx-03	30/08/23
Acura Pharmaceuticals : Termination of Material Agreement - Form 8-K	16/08/23
Acura Pharmaceuticals, Inc. and Zyla Life Sciences, LLC Agree to Terms for the Termination of the Collaboration and License Agreement	16/08/23
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC	28/07/23
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	30/06/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Acura Pharmaceuticals, Inc. Nasdaq

Actions

US00509L8028

Autres langues

Filtres